DEXTECH MEDICAL AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.34 SEK | -1.36% |
|
-12.85% | +10.43% |
| 04-26 | Dextech Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
| 04-15 | DexTech Medical Announces New Positive Results from the Myeloma Study | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Dextech Medical AB is a Sweden-based research company specialized in urologic oncology. It is focused on prostate cancer, but also other cancers and non-malignant diseases. It develops drug canditates based on modified carbohydrate molecule combined with active substances. The Company has a patented technology platform, GuaDex, and three drug candidates with patents or patent applications. The portfolio includes: OsteoDex, for treatment of bone metastases in castration resistant prostate cancer (CRPC); SomaDex, based on endogenous hormone, somatostatin, and aimed at treatment of acromegaly, neuroendocrine tumors and palliative treatment of CRPC; and CatDex, for instillation treatment of bladder cancer.
Calendar
29/08/2024
- Q4 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +10.43% | 7.5M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- DEX Stock
- News Dextech Medical AB
- DexTech's Board Proposes Chairman Candidate
